SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Richard Mazzarella who wrote (645)10/17/1996 6:38:00 PM
From: richard davis   of 4342
 
SSB:

Read the release carefully, only a few were in remission. For instance, the breast cancer patient was not called as being in remission.

Based on how I have read their technology works, 27,1 is supposed to halt the advancement of cancer, not just keep the patient in remission. Therefore, I disagree that the product will only be sold to those in remission.

Question: They mention 9 in the study. I did not count 9 findings in the press release? Did I miss something?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News